Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-04-01

AUTHORS

Beth Hahn, Richard H. Stanford, Alyssa Goolsby Hunter, Breanna Essoi, John White, Riju Ray

ABSTRACT

IntroductionSymptom burden in inadequately controlled chronic obstructive pulmonary disease (COPD) considerably impacts quality of life, healthcare resource utilization (HCRU) and associated costs. This claims-linked cross-sectional survey study assessed symptom burden and HCRU among a prevalent population of COPD patients prescribed long-acting muscarinic antagonist (LAMA) monotherapy.MethodsPatients were identified using claims data from the Optum Research Database. Eligible patients were aged ≥ 40 years with 12 months’ continuous enrollment in a US health plan, ≥ 2 medical claims containing COPD diagnosis codes ≥ 30 days apart, and ≥ 2 claims for LAMA monotherapy in the latter half of the 12-month sample identification period. Patients were mailed a cross-sectional survey assessing patient-reported outcomes (PROs) [COPD assessment test (CAT) and modified medical research council dyspnea scale (mMRC)], clinical characteristics, smoking history, and demographics. Patients also completed the Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) daily diary for 7 days. HCRU was assessed from claims data.ResultsThe study included 433 patients with a self-reported healthcare provider COPD diagnosis, and both claims-based and self-reported LAMA monotherapy treatment (mean age 71.0 years; 59.8% female). Most patients (85.5%) reported a high symptom burden (CAT score ≥ 10), 45.5% had high levels of dyspnea (mMRC grade ≥ 2), and 64.4% reported more severe daily symptoms by the EXACT-PRO. Most patients (71.6%) reported high scores on ≥ 2 PROs. More patients with high symptom burden had COPD-related emergency department visits than those with lower disease burden (27.6% vs 12.7%, P = 0.012).ConclusionsIn conclusion, a large proportion of patients with COPD receiving LAMA monotherapy experienced a high symptom burden and may benefit from therapy escalation. Healthcare professionals can use validated PROs to help them assess symptom burden.FundingGlaxoSmithKline (GSK study number: 205862) More... »

PAGES

69-80

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41030-019-0091-0

DOI

http://dx.doi.org/10.1007/s41030-019-0091-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113176399

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32026428


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "US Value Evidence and Outcomes, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "US Value Evidence and Outcomes, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hahn", 
        "givenName": "Beth", 
        "id": "sg:person.010450153404.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010450153404.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Value Evidence and Outcomes, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "US Value Evidence and Outcomes, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stanford", 
        "givenName": "Richard H.", 
        "id": "sg:person.01352533333.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352533333.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.423532.1", 
          "name": [
            "Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goolsby Hunter", 
        "givenName": "Alyssa", 
        "id": "sg:person.015276716351.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015276716351.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.423532.1", 
          "name": [
            "Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Essoi", 
        "givenName": "Breanna", 
        "id": "sg:person.01270731345.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270731345.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.423532.1", 
          "name": [
            "Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "White", 
        "givenName": "John", 
        "id": "sg:person.014261775431.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014261775431.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "US Medical Affairs, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "US Medical Affairs, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ray", 
        "givenName": "Riju", 
        "id": "sg:person.014530556057.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014530556057.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1465-9921-14-49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051849337", 
          "https://doi.org/10.1186/1465-9921-14-49"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s41030-017-0048-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091308147", 
          "https://doi.org/10.1007/s41030-017-0048-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2466-11-42", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037928349", 
          "https://doi.org/10.1186/1471-2466-11-42"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.4104/pcrj.2010.00059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028207655", 
          "https://doi.org/10.4104/pcrj.2010.00059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12931-017-0548-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084954593", 
          "https://doi.org/10.1186/s12931-017-0548-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-01", 
    "datePublishedReg": "2019-04-01", 
    "description": "IntroductionSymptom burden in inadequately controlled chronic obstructive pulmonary disease (COPD) considerably impacts quality of life, healthcare resource utilization (HCRU) and associated costs. This claims-linked cross-sectional survey study assessed symptom burden and HCRU among a prevalent population of COPD patients prescribed long-acting muscarinic antagonist (LAMA) monotherapy.MethodsPatients were identified using claims data from the Optum Research Database. Eligible patients were aged\u2009\u2265\u200940\u00a0years with 12\u00a0months\u2019 continuous enrollment in a US health plan,\u2009\u2265\u20092 medical claims containing COPD diagnosis codes\u2009\u2265\u200930\u00a0days apart, and\u2009\u2265\u20092 claims for LAMA monotherapy in the latter half of the 12-month sample identification period. Patients were mailed a cross-sectional survey assessing patient-reported outcomes (PROs) [COPD assessment test (CAT) and modified medical research council dyspnea scale (mMRC)], clinical characteristics, smoking history, and demographics. Patients also completed the Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) daily diary for 7\u00a0days. HCRU was assessed from claims data.ResultsThe study included 433 patients with a self-reported healthcare provider COPD diagnosis, and both claims-based and self-reported LAMA monotherapy treatment (mean age 71.0\u00a0years; 59.8% female). Most patients (85.5%) reported a high symptom burden (CAT score\u2009\u2265\u200910), 45.5% had high levels of dyspnea (mMRC grade\u2009\u2265\u20092), and 64.4% reported more severe daily symptoms by the EXACT-PRO. Most patients (71.6%) reported high scores on\u2009\u2265\u20092 PROs. More patients with high symptom burden had COPD-related emergency department visits than those with lower disease burden (27.6% vs 12.7%, P\u2009=\u20090.012).ConclusionsIn conclusion, a large proportion of patients with COPD receiving LAMA monotherapy experienced a high symptom burden and may benefit from therapy escalation. Healthcare professionals can use validated PROs to help them assess symptom burden.FundingGlaxoSmithKline (GSK study number: 205862)", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41030-019-0091-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1136859", 
        "issn": [
          "2364-1754", 
          "2364-1746"
        ], 
        "name": "Pulmonary Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "chronic obstructive pulmonary disease", 
      "healthcare resource utilization", 
      "patient-reported outcomes", 
      "high symptom burden", 
      "muscarinic antagonist (LAMA) monotherapy", 
      "symptom burden", 
      "LAMA monotherapy", 
      "most patients", 
      "claims data", 
      "Optum Research Database", 
      "severe daily symptoms", 
      "patient-reported burden", 
      "US health plan", 
      "obstructive pulmonary disease", 
      "emergency department visits", 
      "low disease burden", 
      "patient survey study", 
      "quality of life", 
      "cross-sectional survey study", 
      "cross-sectional survey", 
      "EXACT-PRO", 
      "eligible patients", 
      "COPD patients", 
      "clinical characteristics", 
      "COPD population", 
      "COPD diagnosis", 
      "monotherapy treatment", 
      "pulmonary disease", 
      "continuous enrollment", 
      "daily symptoms", 
      "more patients", 
      "department visits", 
      "therapy escalation", 
      "diagnosis codes", 
      "disease burden", 
      "ResultsThe study", 
      "monotherapy", 
      "Research Database", 
      "medical claims", 
      "patients", 
      "prevalent population", 
      "healthcare professionals", 
      "health plans", 
      "survey study", 
      "ConclusionsIn conclusion", 
      "daily diaries", 
      "identification period", 
      "burden", 
      "higher scores", 
      "large proportion", 
      "days", 
      "MethodsPatients", 
      "high levels", 
      "dyspnea", 
      "exacerbation", 
      "population", 
      "symptoms", 
      "illness", 
      "disease", 
      "diagnosis", 
      "visits", 
      "study", 
      "months", 
      "demographics", 
      "outcomes", 
      "treatment", 
      "enrollment", 
      "scores", 
      "resource utilization", 
      "escalation", 
      "conclusion", 
      "diary", 
      "professionals", 
      "years", 
      "proportion", 
      "period", 
      "data", 
      "levels", 
      "half", 
      "history", 
      "database", 
      "life", 
      "latter half", 
      "survey", 
      "Long", 
      "quality", 
      "plan", 
      "utilization", 
      "characteristics", 
      "claims", 
      "cost", 
      "code", 
      "IntroductionSymptom burden", 
      "claims-linked cross-sectional survey study", 
      "antagonist (LAMA) monotherapy", 
      "COPD diagnosis codes", 
      "sample identification period", 
      "Chronic Pulmonary Disease Tool (EXACT-PRO) daily diary", 
      "Pulmonary Disease Tool (EXACT-PRO) daily diary", 
      "Disease Tool (EXACT-PRO) daily diary", 
      "Tool (EXACT-PRO) daily diary", 
      "self-reported healthcare provider COPD diagnosis", 
      "healthcare provider COPD diagnosis", 
      "provider COPD diagnosis", 
      "self-reported LAMA monotherapy treatment", 
      "LAMA monotherapy treatment", 
      "COPD-related emergency department visits", 
      "FundingGlaxoSmithKline (GSK study number: 205862) Patient-Reported Burden", 
      "Prevalent COPD Population", 
      "Claims-Linked Patient Survey Study"
    ], 
    "name": "Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study", 
    "pagination": "69-80", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113176399"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41030-019-0091-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32026428"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41030-019-0091-0", 
      "https://app.dimensions.ai/details/publication/pub.1113176399"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_825.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41030-019-0091-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41030-019-0091-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41030-019-0091-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41030-019-0091-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41030-019-0091-0'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      22 PREDICATES      142 URIs      128 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41030-019-0091-0 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 anzsrc-for:1117
4 schema:author N9d23f503c34641f8a5702ad74137f2aa
5 schema:citation sg:pub.10.1007/s41030-017-0048-0
6 sg:pub.10.1186/1465-9921-14-49
7 sg:pub.10.1186/1471-2466-11-42
8 sg:pub.10.1186/s12931-017-0548-3
9 sg:pub.10.4104/pcrj.2010.00059
10 schema:datePublished 2019-04-01
11 schema:datePublishedReg 2019-04-01
12 schema:description IntroductionSymptom burden in inadequately controlled chronic obstructive pulmonary disease (COPD) considerably impacts quality of life, healthcare resource utilization (HCRU) and associated costs. This claims-linked cross-sectional survey study assessed symptom burden and HCRU among a prevalent population of COPD patients prescribed long-acting muscarinic antagonist (LAMA) monotherapy.MethodsPatients were identified using claims data from the Optum Research Database. Eligible patients were aged ≥ 40 years with 12 months’ continuous enrollment in a US health plan, ≥ 2 medical claims containing COPD diagnosis codes ≥ 30 days apart, and ≥ 2 claims for LAMA monotherapy in the latter half of the 12-month sample identification period. Patients were mailed a cross-sectional survey assessing patient-reported outcomes (PROs) [COPD assessment test (CAT) and modified medical research council dyspnea scale (mMRC)], clinical characteristics, smoking history, and demographics. Patients also completed the Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) daily diary for 7 days. HCRU was assessed from claims data.ResultsThe study included 433 patients with a self-reported healthcare provider COPD diagnosis, and both claims-based and self-reported LAMA monotherapy treatment (mean age 71.0 years; 59.8% female). Most patients (85.5%) reported a high symptom burden (CAT score ≥ 10), 45.5% had high levels of dyspnea (mMRC grade ≥ 2), and 64.4% reported more severe daily symptoms by the EXACT-PRO. Most patients (71.6%) reported high scores on ≥ 2 PROs. More patients with high symptom burden had COPD-related emergency department visits than those with lower disease burden (27.6% vs 12.7%, P = 0.012).ConclusionsIn conclusion, a large proportion of patients with COPD receiving LAMA monotherapy experienced a high symptom burden and may benefit from therapy escalation. Healthcare professionals can use validated PROs to help them assess symptom burden.FundingGlaxoSmithKline (GSK study number: 205862)
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N5ec00e081f0142ada83debb3d3a8a291
17 Nee3a5be67cbd44ce889b1a5afb5b9b2d
18 sg:journal.1136859
19 schema:keywords COPD diagnosis
20 COPD diagnosis codes
21 COPD patients
22 COPD population
23 COPD-related emergency department visits
24 Chronic Pulmonary Disease Tool (EXACT-PRO) daily diary
25 Claims-Linked Patient Survey Study
26 ConclusionsIn conclusion
27 Disease Tool (EXACT-PRO) daily diary
28 EXACT-PRO
29 FundingGlaxoSmithKline (GSK study number: 205862) Patient-Reported Burden
30 IntroductionSymptom burden
31 LAMA monotherapy
32 LAMA monotherapy treatment
33 Long
34 MethodsPatients
35 Optum Research Database
36 Prevalent COPD Population
37 Pulmonary Disease Tool (EXACT-PRO) daily diary
38 Research Database
39 ResultsThe study
40 Tool (EXACT-PRO) daily diary
41 US health plan
42 antagonist (LAMA) monotherapy
43 burden
44 characteristics
45 chronic obstructive pulmonary disease
46 claims
47 claims data
48 claims-linked cross-sectional survey study
49 clinical characteristics
50 code
51 conclusion
52 continuous enrollment
53 cost
54 cross-sectional survey
55 cross-sectional survey study
56 daily diaries
57 daily symptoms
58 data
59 database
60 days
61 demographics
62 department visits
63 diagnosis
64 diagnosis codes
65 diary
66 disease
67 disease burden
68 dyspnea
69 eligible patients
70 emergency department visits
71 enrollment
72 escalation
73 exacerbation
74 half
75 health plans
76 healthcare professionals
77 healthcare provider COPD diagnosis
78 healthcare resource utilization
79 high levels
80 high symptom burden
81 higher scores
82 history
83 identification period
84 illness
85 large proportion
86 latter half
87 levels
88 life
89 low disease burden
90 medical claims
91 monotherapy
92 monotherapy treatment
93 months
94 more patients
95 most patients
96 muscarinic antagonist (LAMA) monotherapy
97 obstructive pulmonary disease
98 outcomes
99 patient survey study
100 patient-reported burden
101 patient-reported outcomes
102 patients
103 period
104 plan
105 population
106 prevalent population
107 professionals
108 proportion
109 provider COPD diagnosis
110 pulmonary disease
111 quality
112 quality of life
113 resource utilization
114 sample identification period
115 scores
116 self-reported LAMA monotherapy treatment
117 self-reported healthcare provider COPD diagnosis
118 severe daily symptoms
119 study
120 survey
121 survey study
122 symptom burden
123 symptoms
124 therapy escalation
125 treatment
126 utilization
127 visits
128 years
129 schema:name Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
130 schema:pagination 69-80
131 schema:productId N13614c2f92aa4f72836c99a63ff707eb
132 Na1682398c2be4d41af2ff5fb3ea872a1
133 Nddbb9bb8ebd84c1a868b09b4bb60238e
134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113176399
135 https://doi.org/10.1007/s41030-019-0091-0
136 schema:sdDatePublished 2021-11-01T18:36
137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
138 schema:sdPublisher Nb315759cd338428681681c6785c4ea54
139 schema:url https://doi.org/10.1007/s41030-019-0091-0
140 sgo:license sg:explorer/license/
141 sgo:sdDataset articles
142 rdf:type schema:ScholarlyArticle
143 N13614c2f92aa4f72836c99a63ff707eb schema:name dimensions_id
144 schema:value pub.1113176399
145 rdf:type schema:PropertyValue
146 N3b662d81d15846a0a174f77af64b54c8 rdf:first sg:person.014530556057.09
147 rdf:rest rdf:nil
148 N4106def898434b3cac1afceb036f4057 rdf:first sg:person.015276716351.81
149 rdf:rest Ndc4162f007d64c6bb8fb3c37323114ae
150 N5ec00e081f0142ada83debb3d3a8a291 schema:volumeNumber 5
151 rdf:type schema:PublicationVolume
152 N9d23f503c34641f8a5702ad74137f2aa rdf:first sg:person.010450153404.64
153 rdf:rest Ne68707490e7f417ab901d0aafd531b14
154 Na1682398c2be4d41af2ff5fb3ea872a1 schema:name doi
155 schema:value 10.1007/s41030-019-0091-0
156 rdf:type schema:PropertyValue
157 Nb12d011bac4041f29e4ad148bd3be062 rdf:first sg:person.014261775431.87
158 rdf:rest N3b662d81d15846a0a174f77af64b54c8
159 Nb315759cd338428681681c6785c4ea54 schema:name Springer Nature - SN SciGraph project
160 rdf:type schema:Organization
161 Ndc4162f007d64c6bb8fb3c37323114ae rdf:first sg:person.01270731345.98
162 rdf:rest Nb12d011bac4041f29e4ad148bd3be062
163 Nddbb9bb8ebd84c1a868b09b4bb60238e schema:name pubmed_id
164 schema:value 32026428
165 rdf:type schema:PropertyValue
166 Ne68707490e7f417ab901d0aafd531b14 rdf:first sg:person.01352533333.07
167 rdf:rest N4106def898434b3cac1afceb036f4057
168 Nee3a5be67cbd44ce889b1a5afb5b9b2d schema:issueNumber 1
169 rdf:type schema:PublicationIssue
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
174 schema:name Cardiorespiratory Medicine and Haematology
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
177 schema:name Public Health and Health Services
178 rdf:type schema:DefinedTerm
179 sg:journal.1136859 schema:issn 2364-1746
180 2364-1754
181 schema:name Pulmonary Therapy
182 schema:publisher Springer Nature
183 rdf:type schema:Periodical
184 sg:person.010450153404.64 schema:affiliation grid-institutes:grid.418019.5
185 schema:familyName Hahn
186 schema:givenName Beth
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010450153404.64
188 rdf:type schema:Person
189 sg:person.01270731345.98 schema:affiliation grid-institutes:grid.423532.1
190 schema:familyName Essoi
191 schema:givenName Breanna
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270731345.98
193 rdf:type schema:Person
194 sg:person.01352533333.07 schema:affiliation grid-institutes:grid.418019.5
195 schema:familyName Stanford
196 schema:givenName Richard H.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352533333.07
198 rdf:type schema:Person
199 sg:person.014261775431.87 schema:affiliation grid-institutes:grid.423532.1
200 schema:familyName White
201 schema:givenName John
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014261775431.87
203 rdf:type schema:Person
204 sg:person.014530556057.09 schema:affiliation grid-institutes:grid.418019.5
205 schema:familyName Ray
206 schema:givenName Riju
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014530556057.09
208 rdf:type schema:Person
209 sg:person.015276716351.81 schema:affiliation grid-institutes:grid.423532.1
210 schema:familyName Goolsby Hunter
211 schema:givenName Alyssa
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015276716351.81
213 rdf:type schema:Person
214 sg:pub.10.1007/s41030-017-0048-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091308147
215 https://doi.org/10.1007/s41030-017-0048-0
216 rdf:type schema:CreativeWork
217 sg:pub.10.1186/1465-9921-14-49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051849337
218 https://doi.org/10.1186/1465-9921-14-49
219 rdf:type schema:CreativeWork
220 sg:pub.10.1186/1471-2466-11-42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037928349
221 https://doi.org/10.1186/1471-2466-11-42
222 rdf:type schema:CreativeWork
223 sg:pub.10.1186/s12931-017-0548-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084954593
224 https://doi.org/10.1186/s12931-017-0548-3
225 rdf:type schema:CreativeWork
226 sg:pub.10.4104/pcrj.2010.00059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028207655
227 https://doi.org/10.4104/pcrj.2010.00059
228 rdf:type schema:CreativeWork
229 grid-institutes:grid.418019.5 schema:alternateName US Medical Affairs, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA
230 US Value Evidence and Outcomes, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA
231 schema:name US Medical Affairs, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA
232 US Value Evidence and Outcomes, GSK, 5 Moore Drive, 27709-3398, Research Triangle Park, NC, USA
233 rdf:type schema:Organization
234 grid-institutes:grid.423532.1 schema:alternateName Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA
235 schema:name Health Economics and Outcomes Research, Optum, 11000 Optum Circle, 55344, Eden Prairie, MN, USA
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...